PFE
PfizerPrevious close
30.52
Change
+0.57 / +1.90%
P/E (TTM) ?
40.0
Market Cap
$174B
1M
+7.01%
S&P 500 −0.91% over same period
Volume / Avg Volume
45.5M / 27.6M
1.65× average
Latest earnings analysisFY2026 Q2Reported 2026-08-04
Pfizer Q2 2026: adjusted EPS beat, revenue guidance midpoint raised
Pfizer's second quarter looks ugly on the GAAP line — a $248 million net loss and $(0.04) per share — but that red ink is almost entirely a $4.3 billion non-cash impairment charge. Adjusted EPS of $0.77 beat the $0.6914 consensus, revenue rose 3.0% to $15.03 billion, and Pfizer raised the midpoint of its 2026 revenue guidance. Read the quarter as a beat-and-raise wrapped in an accounting loss.
Read the full analysis →Revenue$15.03BYoY +2.60%
EPS (non-GAAP)$0.77Beatest. $0.69
Next-quarter revenue guidance$61.50B ±1.6%YoY +309.10%
Next-day move+1.57%
Recent Earnings
Click to read the FinDog analysis| Period | Reported | Revenue | Analysis |
|---|---|---|---|
| FY2026 Q2 Quarter ended 2026-06 | 2026-08-04 | $15.0B | Read analysis → |
| FY2026 Q1 Quarter ended 2026-03 | 2026-05-05 | $14.5B | Pending |
| FY2025 Q4 Quarter ended 2025-12 | 2026-02-03 | $62.6B | Pending |
| FY2025 Q3 Quarter ended 2025-09 | 2025-11-04 | $16.7B | Pending |
| FY2025 Q2 Quarter ended 2025-06 | 2025-08-05 | $14.7B | Pending |
| FY2025 Q1 Quarter ended 2025-03 | 2025-04-29 | $13.7B | Pending |
Decision Panel
Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market dataValuation
P/E is at percentile 90 of its 5-year rangeExpensive
5-year range 8.9 – 73.5 · Median 18.1
No buybacks or dividends in the last four quarters
P/E (TTM)
40.0
P/B
2.0
P/S
2.7
Dividend Yield
5.38%
Earnings Reaction
Over the last 6 reports, the stock moved ±2.2% on average on the first trading day after, rising 5 times
Most recent +1.57%
Volatility & Correlation
1-year beta -0.12 · Correlation with S&P 500 -0.07Low beta
Annualized volatility 20% vs. 12% for the S&P 500
Insider Trading
View all →Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions
Buy 3 · $3.0MSell 1 · $0.08MNet buying $2.9M
- 08-12BOURLA ALBERTChairman & CEOBuy$1.0M38,000 shares · Avg price 26.34
- 08-05Buckley Mortimer JDirectorBuy$0.96M37,632 shares · Avg price 25.52
- 08-05BLAYLOCK RONALD EDirectorBuy$1.00M39,231 shares · Avg price 25.46
- 08-05DAMICO JENNIFER B.SVP & ControllerSell$0.08M3,278 shares · Avg price 25.40
Multi-Quarter Financial Trends
View all quarters →Last 12 quarters · As reported by the company
| Quarter | Revenue ($B) | YoY | Gross Margin | Net Income ($B) | EPS |
|---|---|---|---|---|---|
| FY2026 Q2 | 15.03 | +2.6% | 72.8% | -0.25 | -0.04 |
| FY2026 Q1 | 14.45 | +5.4% | 75.4% | 2.69 | 0.47 |
| FY2025 Q4 | 17.56 | −1.2% | 70.0% | -1.65 | -0.29 |
| FY2025 Q3 | 16.65 | −5.9% | 74.9% | 3.54 | 0.62 |
| FY2025 Q2 | 14.65 | +10.3% | 74.2% | 2.91 | 0.51 |
| FY2025 Q1 | 13.72 | −7.8% | 79.3% | 2.97 | 0.52 |
| FY2024 Q4 | 17.76 | +21.9% | 66.7% | 0.41 | 0.07 |
| FY2024 Q3 | 17.70 | +31.2% | 70.3% | 4.47 | 0.78 |
| FY2024 Q2 | 13.28 | +2.1% | 75.2% | 0.04 | 0.01 |
| FY2024 Q1 | 14.88 | −19.5% | 77.3% | 3.12 | 0.55 |
| FY2023 Q4 | 14.57 | −42.0% | 48.1% | -3.37 | -0.59 |
| FY2023 Q3 | 13.49 | −40.4% | 31.3% | -2.38 | -0.42 |
| Ticker | P/E | Revenue YoY | Gross Margin | 1M | View |
|---|---|---|---|---|---|
| PFE | 40.0 | +2.6% | 72.8% | +7.01% | Neutral |
| LLY | 50.2 | +38.6% | 83.9% | +22.51% | Bullish |
| JNJ | 41.3 | +5.9% | 68.1% | +3.20% | Bullish |
| ABBV | 81.4 | +10.2% | 74.7% | +12.73% | Bullish |
| UNH | 23.0 | +0.4% | 88.1% | +10.87% | Bullish |
| MRK | 117.2 | +5.1% | 73.5% | +2.90% | Neutral |
| TMO | 36.4 | +9.1% | — | +3.25% | Neutral |
| AMGN | 28.5 | +9.5% | 72.0% | +10.56% | Bullish |
| GILD | — | +6.8% | 81.1% | +14.51% | Neutral |